# A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

> **NCT05956626** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Ocugen** · enrollment: 51 (estimated)

## Conditions studied

- Stargardt Disease

## Interventions

- **DRUG:** OCU410ST

## Key facts

- **NCT ID:** NCT05956626
- **Lead sponsor:** Ocugen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-25
- **Primary completion:** 2026-09-28
- **Final completion:** 2026-09-28
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05956626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05956626, "A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05956626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*